Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02596802 · ClinicalTrials.gov registry record · NA

Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia

A NA study of Congenital Diaphragmatic Hernia, sponsored by Anthony Johnson.

Active
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT02596802 is a NA study of Congenital Diaphragmatic Hernia that is active but no longer recruiting, run by Anthony Johnson. The registered enrollment target is 22 participants, below the 195-participant average among 22 other Congenital Diaphragmatic Hernia trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02596802, a NA study of Congenital Diaphragmatic Hernia, is active but no longer recruiting, sponsored by Anthony Johnson.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The goal is to assess the feasibility and safety of implementing Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy in fetuses with severe left Congenital Diaphragmatic Hernia (CDH) at UTHealth. UTHealth's success in this study (with an initial 5 patients) will determine the feasibility of UTHealth's future participation in multi-center trials of this intervention.

Interventions

  • DEVICE FETO therapy

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2015-12-01
Est. Completion 2026-01-20
Phase NA

Sponsor

Anthony Johnson

1 total trials

What the Registry Record Tells You About NCT02596802

The ClinicalTrials.gov registry entry for NCT02596802 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 195-participant average among 22 other Congenital Diaphragmatic Hernia trials with a reported enrollment target (89% lower). The listed sponsor is Anthony Johnson, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Congenital Diaphragmatic Hernia appearing as the primary indexed condition, and to 1 intervention - of which FETO therapy is the first listed.

NCT02596802 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT02596802 about?

NCT02596802 is a clinical study titled "Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia". The goal is to assess the feasibility and safety of implementing Fetoscopic Endoluminal Tracheal Occlusion (FETO) therapy in fetuses with severe left Congenital Diaphragmatic Hernia (CDH) at UTHealth. UTHealth's success in this study (with an initial 5 patients) will determine the feasibility of UTH...

What is the current status of trial NCT02596802?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2015-12-01. Estimated completion is 2026-01-20.

What conditions does trial NCT02596802 study?

This clinical trial studies the following conditions: Congenital Diaphragmatic Hernia.

What interventions are being tested in trial NCT02596802?

The interventions under investigation include: FETO therapy (DEVICE).

Who is sponsoring clinical trial NCT02596802?

This trial is sponsored by Anthony Johnson, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02596802 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Congenital Diaphragmatic Hernia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.